To assess whether ZIKV directly affects AD pathology through PERK-eIF2α activation, GSK2656157 (PERK inhibitor, PERKi), an inhibitor of the upstream factor, was treated in ZIKV-infected organoids. Here, EIF2A is linked to Alzheimer disease.